|
Patient characteristics |
|
| Characteristics |
Patients |
|
|
|
| Entered |
8 |
| Karnofsky performance score |
90–100% |
| Age (years) |
|
| Median (range) |
65.5 years (range 53 – 73 y) |
| Stage (primary diagnosis) |
|
| I |
- |
| II |
6 (75%) |
| III |
- |
| IV |
1 (12.5%) |
| Not available |
1 (12.5%) |
| Ductal/Lobular |
7/0 |
| Not available |
1 (12.5%) |
| Grading |
|
| 1 |
- |
| 2 |
2 (25%) |
| 3 |
5 (62.5%) |
| Not available |
1 (12.5%) |
| Estrogens receptor/progesteron receptor positive |
7/6 |
| Her2 Status positive/negative (IHC/FISH*) |
0/8 |
| Adjuvant chemotherapy |
3 (37.5%) |
| Adjuvant endocrine therapy |
3 (37.5%) |
| Palliative endocrine therapy |
4 (50%) |
| Prior anthracycline exposure |
5 (62.5%) |
| Prior capecitabine exposure |
2 (25%) |
| Time to recurrence |
|
| Median (range) |
87 months (13 – 148 m) |
| Treatment line |
|
| First line |
4 (50%) |
| Second line |
2 (25%) |
| >/= Third line |
2 (25%) |
| Metastatic sites |
|
| Median (range) |
2 (range 1 – 4) |
| bones/soft tissue only |
3 (37.5%) |
| visceral only |
- |
| both |
5 (62.5%) |
| Localisation |
|
| Lung |
1 |
| Liver |
3 |
| Bones |
5 |
| Lymph nodes |
6 |
| Soft tissue |
2 |
| Brain |
1 |
| Skin |
1 |
| More than one metastatic site |
7 (87.5%) |
|
* IHC: immunohistochemistry, Herceptest® (Dako A/S, Glostrup, Denmark); FISH: dual colour fluorescent in situ hybridization (PathVision® HER2 DNA probe kit, Vysis, Downers Grove, IL, USA) | |
Bartsch et al. BMC Clinical Pharmacology 2007 7:7 doi:10.1186/1472-6904-7-7 |
|